tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
rosuvacard 10 mg apvalkotās tabletes
zentiva, k.s., czech republic - rosuvastatīns - apvalkotā tablete - 10 mg
rosuvacard 20 mg apvalkotās tabletes
zentiva, k.s., czech republic - rosuvastatīns - apvalkotā tablete - 20 mg
rosuvacard 40 mg apvalkotās tabletes
zentiva, k.s., czech republic - rosuvastatīns - apvalkotā tablete - 40 mg
rosulip 40 mg/10 mg cietās kapsulas
egis pharmaceuticals plc, hungary - rosuvastatinum, ezetimibum - kapsula, cietā - 40 mg/10 mg
rosuvastatin accord 10 mg apvalkotās tabletes
accord healthcare b.v., netherlands - rosuvastatīns - apvalkotā tablete - 10 mg
rosulip 20 mg/10 mg cietās kapsulas
egis pharmaceuticals plc, hungary - rosuvastatinum, ezetimibum - kapsula, cietā - 20 mg/10 mg
rosuvastatin accord 20 mg apvalkotās tabletes
accord healthcare b.v., netherlands - rosuvastatīns - apvalkotā tablete - 20 mg
rosuvastatin accord 40 mg apvalkotās tabletes
accord healthcare b.v., netherlands - rosuvastatīns - apvalkotā tablete - 40 mg
rosuvastatin accord 5 mg apvalkotās tabletes
accord healthcare b.v., netherlands - rosuvastatīns - apvalkotā tablete - 5 mg